On Friday, October 13, 2017, Brighter AB's ("Brighter") warrants of series TO4 2017/2020, which was announced in conjunction with Brighter convertible notes series KV2 2017/2019 in September 2017, will be listed for trading.
25 August 2020 up until 8 September 2020.
Holders of warrants series TO4 2017/2020 for a total value of SEK 500,000 or more may always exercise the warrants for subscription of shares, i.e. from the date of listing to and including September 8, 2020.
For terms and conditions of the Warrants, please visit:
For more information, please contact:
Truls Sjöstedt, CEO
Tel: +46 709 73 46 00
Henrik Norström, COO
Tel: +46 733 40 30 45
About Brighter AB (publ)
Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter's cloud-based service that continuously collects, analyzes and shares data on the user's terms.
The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter's Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 - 454 32 50, CorporateFinance@remium.com,www.remium.com.
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 11:45 CET on October 6, 2017.
This information was distributed by Cision http://www.cisionwire.se/